Publications
6 shownIncreased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
In patients with metastatic pancreatic adenocarcinoma, nab-paclitaxel plus gemcitabine significantly improved overall survival, progression-free survival, and response rate, but...
Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
No treatment options are available for patients with metastatic colorectal cancer that progresses after all approved standard therapies, but many patients maintain a good perfor...
Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal Cancer
A combination of encorafenib, cetuximab, and binimetinib resulted in significantly longer overall survival and a higher response rate than standard therapy in patients with meta...
Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer
ClinicalTrials.gov Identifier: NCT02494583.
Frequent Co-Authors
Researcher Info
- h-index
- 6
- Publications
- 6
- Citations
- 16,737
- Institution
- Universitat Autònoma de Barcelona
External Links
Identifiers
- ORCID
- 0000-0002-2495-8139
Impact Metrics
h-index
6
h-index: Number of publications with at least h citations each.